CO2022014137A2 - Inhibidores de rip1k - Google Patents
Inhibidores de rip1kInfo
- Publication number
- CO2022014137A2 CO2022014137A2 CONC2022/0014137A CO2022014137A CO2022014137A2 CO 2022014137 A2 CO2022014137 A2 CO 2022014137A2 CO 2022014137 A CO2022014137 A CO 2022014137A CO 2022014137 A2 CO2022014137 A2 CO 2022014137A2
- Authority
- CO
- Colombia
- Prior art keywords
- rip1k
- inhibitors
- kinase
- inhibitory compounds
- rip1
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
En la presente descripción se describen compuestos inhibidores de quinasa, tales como los compuestos inhibidores de la proteína quinasa 1 que interactúa con el receptor (RIP1), así como también composiciones farmacéuticas y combinaciones que comprenden tales compuestos inhibidores. Los compuestos, composiciones farmacéuticas y/o combinaciones descritos pueden usarse para tratar o prevenir una enfermedad o afección asociada a quinasas, particularmente una enfermedad o afección asociada a RIP1.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063004404P | 2020-04-02 | 2020-04-02 | |
PCT/US2021/025598 WO2021203011A1 (en) | 2020-04-02 | 2021-04-02 | Rip1k inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
CO2022014137A2 true CO2022014137A2 (es) | 2023-03-07 |
Family
ID=75747027
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CONC2022/0014137A CO2022014137A2 (es) | 2020-04-02 | 2022-09-30 | Inhibidores de rip1k |
Country Status (20)
Country | Link |
---|---|
US (2) | US11584758B2 (es) |
EP (1) | EP4126864A1 (es) |
JP (1) | JP2023520046A (es) |
KR (1) | KR20220161433A (es) |
CN (1) | CN115867548A (es) |
AR (1) | AR121717A1 (es) |
AU (1) | AU2021246147B2 (es) |
BR (1) | BR112022019492A2 (es) |
CA (1) | CA3173432A1 (es) |
CL (1) | CL2022002695A1 (es) |
CO (1) | CO2022014137A2 (es) |
CR (1) | CR20220492A (es) |
DO (1) | DOP2022000215A (es) |
EC (1) | ECSP22076856A (es) |
IL (1) | IL296916A (es) |
JO (1) | JOP20220246A1 (es) |
MX (1) | MX2022012305A (es) |
PE (1) | PE20230560A1 (es) |
TW (1) | TW202204364A (es) |
WO (1) | WO2021203011A1 (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2016287581B2 (en) * | 2015-07-02 | 2019-06-06 | F. Hoffmann-La Roche Ag | Bicyclic lactams and methods of use thereof |
EA202092581A1 (ru) | 2018-05-03 | 2021-04-08 | Ригел Фармасьютикалз, Инк. | Соединения, ингибирующие rip1, а также способы их получения и применения |
JOP20220056A1 (ar) | 2019-09-06 | 2023-01-30 | Rigel Pharmaceuticals Inc | مركبات rip1 تثبيطية وطرق عملها واستخدامها |
US11479543B2 (en) | 2019-09-06 | 2022-10-25 | Rigel Pharmaceuticals, Inc. | Heterocyclic RIP1 kinase inhibitors |
MX2022010693A (es) * | 2020-02-28 | 2022-09-26 | Univ Texas | Compuestos, composiciones y metodos para inhibidores de la proteina quinasa que interactua con el receptor i para el tratamiento de enfermedades. |
AR122703A1 (es) | 2020-07-01 | 2022-09-28 | Rigel Pharmaceuticals Inc | Inhibidores de rip1k |
WO2023137035A1 (en) * | 2022-01-12 | 2023-07-20 | Denali Therapeutics Inc. | Crystalline forms of (s)-5-benzyl-n-(5-methyl-4-oxo-2, 3,4,5- tetrahydropyrido [3,2-b] [l,4]oxazepin-3-yl)-4h-l,2,4-triazole-3-carboxamide |
CN116478150A (zh) * | 2022-01-21 | 2023-07-25 | 中国科学院上海药物研究所 | 具有ripk1抑制活性的化合物、其制备方法及其用途 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI637951B (zh) | 2013-02-15 | 2018-10-11 | 英商葛蘭素史克智慧財產發展有限公司 | 作為激酶抑制劑之雜環醯胺類 |
AU2016287581B2 (en) | 2015-07-02 | 2019-06-06 | F. Hoffmann-La Roche Ag | Bicyclic lactams and methods of use thereof |
AU2016340527B2 (en) | 2015-10-23 | 2020-09-17 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
CR20180413A (es) * | 2016-02-05 | 2018-12-04 | Denali Therapeutics Inc | Inhibidores de la proteína quinasa 1 que interactua con el receptor |
CA3068305A1 (en) * | 2017-06-29 | 2019-01-03 | Rigel Pharmaceuticals, Inc. | Kinase inhibitors and methods for making and using |
WO2019204537A1 (en) * | 2018-04-20 | 2019-10-24 | Genentech, Inc. | N-[4-oxo-2,3-dihydro-1,5-benzoxazepin-3-yl]-5,6-dihydro-4h-pyrrolo[1,2-b]pyrazol e-2-carboxamide derivatives and related compounds as rip1 kinase inhibitors for treating e.g. irritable bowel syndrome (ibs) |
EA202092581A1 (ru) | 2018-05-03 | 2021-04-08 | Ригел Фармасьютикалз, Инк. | Соединения, ингибирующие rip1, а также способы их получения и применения |
EP3788044B1 (en) | 2018-05-03 | 2023-08-09 | Rigel Pharmaceuticals, Inc. | Rip1 inhibitory compounds and methods for making and using the same |
KR20210024574A (ko) | 2018-06-26 | 2021-03-05 | 상하이 인스티튜트 오브 오가닉 케미스트리, 차이니즈 아카데미 오브 사이언시스 | 세포 괴사 억제제 및 이의 제조 방법과 용도 |
CN109134448B (zh) * | 2018-10-16 | 2020-11-27 | 中南大学湘雅医院 | 杂环化合物及其盐、制备方法、用途和药物 |
BR112021024116A2 (pt) | 2019-05-31 | 2022-01-11 | Medshine Discovery Inc | Composto bicíclico como inibidor de rip-1 quinase e aplicação do mesmo |
US11479543B2 (en) | 2019-09-06 | 2022-10-25 | Rigel Pharmaceuticals, Inc. | Heterocyclic RIP1 kinase inhibitors |
CN115298184A (zh) | 2019-11-07 | 2022-11-04 | 里格尔药品股份有限公司 | 杂环rip1抑制化合物 |
-
2021
- 2021-03-31 AR ARP210100820A patent/AR121717A1/es unknown
- 2021-04-01 TW TW110112096A patent/TW202204364A/zh unknown
- 2021-04-02 AU AU2021246147A patent/AU2021246147B2/en active Active
- 2021-04-02 CR CR20220492A patent/CR20220492A/es unknown
- 2021-04-02 EP EP21722607.5A patent/EP4126864A1/en active Pending
- 2021-04-02 BR BR112022019492A patent/BR112022019492A2/pt unknown
- 2021-04-02 JP JP2022559872A patent/JP2023520046A/ja active Pending
- 2021-04-02 IL IL296916A patent/IL296916A/en unknown
- 2021-04-02 US US17/221,493 patent/US11584758B2/en active Active
- 2021-04-02 MX MX2022012305A patent/MX2022012305A/es unknown
- 2021-04-02 WO PCT/US2021/025598 patent/WO2021203011A1/en active Application Filing
- 2021-04-02 KR KR1020227037796A patent/KR20220161433A/ko active Search and Examination
- 2021-04-02 CN CN202180038481.3A patent/CN115867548A/zh active Pending
- 2021-04-02 CA CA3173432A patent/CA3173432A1/en active Pending
- 2021-04-02 PE PE2022002161A patent/PE20230560A1/es unknown
-
2022
- 2022-09-30 EC ECSENADI202276856A patent/ECSP22076856A/es unknown
- 2022-09-30 DO DO2022000215A patent/DOP2022000215A/es unknown
- 2022-09-30 CO CONC2022/0014137A patent/CO2022014137A2/es unknown
- 2022-09-30 CL CL2022002695A patent/CL2022002695A1/es unknown
- 2022-10-04 JO JOP/2022/0246A patent/JOP20220246A1/ar unknown
-
2023
- 2023-01-13 US US18/154,255 patent/US20230227469A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2023520046A (ja) | 2023-05-15 |
WO2021203011A1 (en) | 2021-10-07 |
CA3173432A1 (en) | 2021-10-07 |
PE20230560A1 (es) | 2023-03-31 |
EP4126864A1 (en) | 2023-02-08 |
KR20220161433A (ko) | 2022-12-06 |
BR112022019492A2 (pt) | 2022-11-16 |
IL296916A (en) | 2022-12-01 |
US11584758B2 (en) | 2023-02-21 |
CL2022002695A1 (es) | 2023-08-11 |
US20210317135A1 (en) | 2021-10-14 |
ECSP22076856A (es) | 2023-02-28 |
AU2021246147B2 (en) | 2024-01-18 |
MX2022012305A (es) | 2023-03-06 |
AR121717A1 (es) | 2022-06-29 |
CN115867548A (zh) | 2023-03-28 |
DOP2022000215A (es) | 2023-02-28 |
TW202204364A (zh) | 2022-02-01 |
AU2021246147A1 (en) | 2022-10-20 |
JOP20220246A1 (ar) | 2023-01-30 |
CR20220492A (es) | 2023-02-09 |
US20230227469A1 (en) | 2023-07-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DOP2022000051A (es) | Compuestos inhibidores de rip1 y métodos para hacer y utilizar los mismos | |
DOP2023000169A (es) | Compuestos inhibidores de rip1 y métodos para preparar y usar los mismos | |
DOP2022000215A (es) | Inhibidores de rip1k | |
ECSP20077518A (es) | Compuestos inhibidores de rip1 y métodos para preparar y usar los mismos | |
DOP2022000042A (es) | Compuestos inhibidores de rip1 y métodos para prepararlos y usarlos | |
CO2023000051A2 (es) | Inhibidores de rip1k | |
AR120412A1 (es) | Compuestos heterocíclicos inhibidores de rip1 | |
CO2023012077A2 (es) | Inhibidores heterocíclicos de la cinasa rip1 |